JP7677995B2 - ガレクチン－３の低分子阻害剤 - Google Patents
ガレクチン－３の低分子阻害剤 Download PDFInfo
- Publication number
- JP7677995B2 JP7677995B2 JP2022568549A JP2022568549A JP7677995B2 JP 7677995 B2 JP7677995 B2 JP 7677995B2 JP 2022568549 A JP2022568549 A JP 2022568549A JP 2022568549 A JP2022568549 A JP 2022568549A JP 7677995 B2 JP7677995 B2 JP 7677995B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- alkyl
- carboxylate
- give
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022627P | 2020-05-11 | 2020-05-11 | |
| US63/022,627 | 2020-05-11 | ||
| PCT/US2021/031479 WO2021231243A1 (en) | 2020-05-11 | 2021-05-10 | Small molecule inhibitors of galectin-3 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023525527A JP2023525527A (ja) | 2023-06-16 |
| JPWO2021231243A5 JPWO2021231243A5 (https=) | 2024-05-20 |
| JP2023525527A5 JP2023525527A5 (https=) | 2024-05-20 |
| JP7677995B2 true JP7677995B2 (ja) | 2025-05-15 |
Family
ID=76284161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568549A Active JP7677995B2 (ja) | 2020-05-11 | 2021-05-10 | ガレクチン－３の低分子阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12286424B2 (https=) |
| EP (1) | EP4149939A1 (https=) |
| JP (1) | JP7677995B2 (https=) |
| KR (1) | KR20230009433A (https=) |
| CN (1) | CN115551850A (https=) |
| WO (1) | WO2021231243A1 (https=) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020519625A (ja) | 2017-05-12 | 2020-07-02 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 疾患の予防および治療用の化合物およびその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| JP2015535233A (ja) | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| JP6904906B2 (ja) | 2015-01-30 | 2021-07-21 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| ES2921500T3 (es) | 2015-11-09 | 2022-08-26 | Galecto Biotech Ab | 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas |
| US20200061095A1 (en) * | 2017-05-12 | 2020-02-27 | Galectin Sciences, Llc | Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof |
| EP3953349A1 (en) * | 2019-04-10 | 2022-02-16 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
-
2021
- 2021-05-10 EP EP21730348.6A patent/EP4149939A1/en active Pending
- 2021-05-10 US US17/998,261 patent/US12286424B2/en active Active
- 2021-05-10 JP JP2022568549A patent/JP7677995B2/ja active Active
- 2021-05-10 KR KR1020227042914A patent/KR20230009433A/ko active Pending
- 2021-05-10 WO PCT/US2021/031479 patent/WO2021231243A1/en not_active Ceased
- 2021-05-10 CN CN202180034243.5A patent/CN115551850A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020519625A (ja) | 2017-05-12 | 2020-07-02 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 疾患の予防および治療用の化合物およびその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230212158A1 (en) | 2023-07-06 |
| JP2023525527A (ja) | 2023-06-16 |
| CN115551850A (zh) | 2022-12-30 |
| US12286424B2 (en) | 2025-04-29 |
| KR20230009433A (ko) | 2023-01-17 |
| WO2021231243A1 (en) | 2021-11-18 |
| EP4149939A1 (en) | 2023-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112770745B (zh) | 用于治疗特定白血病的化合物 | |
| CN114025844B (zh) | 蛋白酪氨酸磷酸酶抑制剂及其使用方法 | |
| JP2026063013A (ja) | ヘテロ環ｇｌｐ－１アゴニスト | |
| WO2023045960A1 (zh) | 一种吡啶类衍生物及其用途 | |
| RU2666349C2 (ru) | Новое конденсированное пиримидиновое соединение или его соль | |
| TW201630907A (zh) | ＴＧＦβＲ拮抗劑 | |
| CN105541693B (zh) | 芳杂环类衍生物及其在药物上的应用 | |
| CN109689664B (zh) | 作为par4抑制剂的三环杂芳基取代的喹啉和氮杂喹啉化合物 | |
| JP7478165B2 (ja) | ガレクチン－３の低分子阻害剤 | |
| TW202430522A (zh) | 一種用於ｂｃｌ－２蛋白靶向降解的嵌合體化合物、其製備方法及其在醫藥上的應用 | |
| CN110272425B (zh) | 吡啶酰基八氢吡咯并[3,4-c]吡咯衍生物及其用途 | |
| CN114980975A (zh) | 二氢环戊二烯并异喹啉磺酰胺衍生物 | |
| WO2023016521A1 (zh) | 取代三唑类衍生物、其制备方法、药物组合物和用途 | |
| CN107207516B (zh) | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 | |
| JP7677995B2 (ja) | ガレクチン－３の低分子阻害剤 | |
| WO2024175121A1 (zh) | α，β-不饱和酰胺类化合物及其应用 | |
| CN121443603A (zh) | 能够用于治疗smarca4缺失型癌症的作为smarca2抑制剂的1,6-萘啶化合物 | |
| CN110167946A (zh) | 具有tnap抑制活性的磺酰胺化合物 | |
| CN115551855A (zh) | 半乳凝素-3的小分子抑制剂 | |
| WO2024245193A1 (zh) | 杂芳环类化合物、其药物组合物及其应用 | |
| HK40052099A (en) | Compounds for treating certain leukemias | |
| HK40052099B (en) | Compounds for treating certain leukemias | |
| KR20240054994A (ko) | AhR 시그널링의 조절에 유용한 화합물 | |
| HK40121127A (zh) | 杂环glp-1激动剂 | |
| WO2025218811A1 (zh) | pan-KRAS靶向蛋白降解剂及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240509 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240509 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250318 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250325 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250407 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250422 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250501 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7677995 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |